Hemispherx treats first patient in clinical trial of Ampligen
Category: #health  | By Nikita Chaurasia  | Date: 2019-06-14 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Hemispherx treats first patient in clinical trial of Ampligen

Hemispherx Biopharma Inc., a US-based biopharmaceutical company recently announced having treated its first patient with Ampligen in combination with Cisplatin & Pembrolizumab, in a phase 2 ovarian cancer clinical trial.

As per credible sources, the study is evaluating Hemispherx' patented experimental drug Ampligen in combination with cisplatin and pembrolizumab, an anti-PD-1 check-point blockade therapy, under the leadership of principal investigator Robert Edwards. The study is expected to treat 45 patients. It is a second periodic ovarian cancer trial of Ampligen at University of Pittsburgh Medical Centre (UPMC).

For the record, Hemispherx Biopharma, Inc. is a pharmaceutical company, focused on R&D of therapeutics to treat multiple types of cancer. The company’s flagship product includes Ampligen and Alferon N Injection. Based on pre-clinical studies & clinical trials of Amligen, Hemispherx concluded the drug to have broad-spectrum anti-cancer & anti-viral properties. Already conducted clinical trials of Ampligen includes studies of potential treatment of cancer patients with malignant melanoma and renal cell carcinoma.

As per sources close to the matter, a phase 1/2 study was initiated approximately 3 years ago & is near completion of the phase 1 portion. The clinical outcome from initial phase 1/2 clinical trial of recurring ovarian cancer is being drafted by Dr. Edwards' team.

Dr. Edwards, chairman of gynecology services at UPMC’s Magee-Women's Hospital, Professor of Obstetrics, Gynecology & Reproductive Services at UPMC, was reported to say that the initial trial of Ampligen indicates that the drug is generally well-tolerated through intraperitoneal supervision and thus paved way for the new phase 2 study, combining Ampligen with pembrolizumab. Ampligen contains strong killer T-cell that can stay in tumor microenvironment without attracting regulatory T cells. The drug has the potential to be clinically significant by helping optimize barrier block induced tumor shrinkage.

Thomas K. Equels, CEO, Hemispherx, was reportedly quoted saying that Ovarian cancer is anticipated to kill 152,000 women this year world-wide. In the new study Hemispherx & the team at Magee-Women's Hospital of UPMC are focused on developing a life-saving therapy to meet this critical need.

Source credits: https://hemispherx.irpass.com/Hemispherx-Biopharma-Announces-First-Patient-Treated-in-Phase-2-Ovarian-Cancer-Clinical-Trial-Evalua

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

General Motors passes Ford to become the second-best EV seller in U.S.

General Motors passes Ford to become the second-best EV seller in U.S.

By Nikita Chaurasia

Detroit-based American multinational automaker, General Motors, has reportedly pulled ahead of fellow American rival, Ford Motor, to establish itself as second-biggest seller of all-electric vehicles in the US during the first quarter of 2023. The...

McKinsey commences job cuts focused on non-client serving teams

McKinsey commences job cuts focused on non-client serving teams

By Nikita Chaurasia

McKinsey and Co. a consulting giant entity has decided to start cutting jobs in one of the biggest rounds of layoffs for the company. This is likely to eliminate the jobs of about 2000 employees from work. The layoffs will be focused on support st...

Fintech firm PayPal to shed around 2000 staff as global economy plummets

Fintech firm PayPal to shed around 2000 staff as global economy plummets

By Nikita Chaurasia

PayPal, the U.S.-based fintech giant, has reportedly announced that it will cut nearly 2000 jobs, approximately 7% of its workforce, as it turns the latest prominent tech company to shed staff in a bid to cut costs. The online payments provider cl...